Cargando…
Reversal of CD8 T-Cell–Mediated Mucocutaneous Graft-Versus-Host-Like Disease by the JAK Inhibitor Tofacitinib
The utility of allogeneic hematopoietic stem cell transplantation is limited by graft-versus-host disease (GVHD), a significant cause of morbidity and mortality. Patients with GVHD exhibit cutaneous manifestations with histological features of interface dermatitis followed by scleroderma-like change...
Autores principales: | Okiyama, Naoko, Furumoto, Yasuko, Villarroel, Vadim A, Linton, Jay T, Tsai, Wanxia L, Gutermuth, Jan, Ghoreschi, Kamran, Gadina, Massimo, O'Shea, John J, Katz, Stephen I |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3961527/ https://www.ncbi.nlm.nih.gov/pubmed/24213371 http://dx.doi.org/10.1038/jid.2013.476 |
Ejemplares similares
-
Identification of CD3(+)CD4(-)CD8(-)T cells as potential regulatory cells in an experimental murine model of graft vs. host skin disease (GvHD)
por: Miyagawa, Fumi, et al.
Publicado: (2013) -
Editorial: JAK inhibition in autoimmune and inflammatory diseases
por: Telliez, Jean-Baptiste, et al.
Publicado: (2022) -
Tofacitinib inhibits the development of experimental autoimmune uveitis and reduces the proportions of Th1 but not of Th17 cells
por: Bing, So Jin, et al.
Publicado: (2020) -
JAK Inhibition Differentially Affects NK Cell and ILC1 Homeostasis
por: Vian, Laura, et al.
Publicado: (2019) -
Emerging Topical and Systemic JAK Inhibitors in Dermatology
por: Solimani, Farzan, et al.
Publicado: (2019)